Table 1.
Demographic and clinical features of study participants
| CU | CI-NAD | CI-AD | P-value | ||
|---|---|---|---|---|---|
| ANOVA b | CI-NAD vs CI-AD c | ||||
| N | 13 | 38 | 34 | ||
| Age (years) | 69.6 (7.1) | 69.8 (7.4) | 70.8 (6.1) | .796 | > .999 |
| Female | 7 (54%) | 21 (55%) | 16 (47%) | .775 | .487 |
| Education (years) | 9.1 (5.2) | 8.5 (3.9) | 8.7 (4.5) | > .999 | > .999 |
| Body mass indexa | 25.0 (3.4) | 25.3 (3.8) | 24.9 (2.9) | > .999 | > .999 |
| APOEe4 carrier statusd | 2 (18%) | 3 (9%) | 20 (65%) | < .001 | < .001 |
| General cognition | |||||
| Mini-Mental State Examination | 28.3 (1.2) | 24.8 (3.9) | 22.2 (5.1) | < .001 | 0.101 |
| ADAScog | 8.2 (3.3) | 15.3 (9.5) | 17.1 (7.6) | < .001 | .330 |
| Clinical stage | |||||
| Mild cognitive impairment | - | 21 (55%) | 22 (65%) | .415 | |
| Dementia | - | 17 (45%) | 12 (35%) | .415 | |
| Amyloid load (PET SUVr) | .95 (.07) | .92 (.09) | 1.31 (.13) | < .001 | < .001 |
Figure denotes mean (SD) and number (%)
Abbreviations: CU: cognitively unimpaired persons; CI-NAD: patients with cognitive impairment not due to AD; CI-AD: patients with cognitive impairment due to AD; ADAScog: Alzheimer's Disease Assessment Scale, cognitive subscale; PET: Positron emission tomography; SUVr: Standardized uptake value ratio
a Weight/height2 and measured in kg/cm2
b Statistical difference among the 3 groups by ANOVA, Kruskal–Wallis, or chi-squared test
c P values of pairwise comparisons using Bonferroni correction
d Missing data for 8 participants: 2 in CU, 4 in CI-NAD, and 3 in CI-AD